Literature DB >> 20682186

Factors associated with complicated buprenorphine inductions.

Susan D Whitley1, Nancy L Sohler, Hillary V Kunins, Angela Giovanniello, Xuan Li, Galit Sacajiu, Chinazo O Cunningham.   

Abstract

Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment in an urban community health center. The primary outcome, defined as complicated induction (precipitated or protracted withdrawal), was observed in 18 (16.8%) patients. Complicated inductions were associated with poorer treatment retention (than routine inductions) and decreased over time. Factors independently associated with complicated inductions included recent use of prescribed methadone, recent benzodiazepine use, no prior experience with buprenorphine, and a low initial dose of buprenorphine/naloxone. Findings from this study and further investigation of patient characteristics and treatment characteristics associated with complicated inductions can help guide buprenorphine treatment strategies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682186      PMCID: PMC4755478          DOI: 10.1016/j.jsat.2010.04.001

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  14 in total

1.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

2.  The first three years of buprenorphine in the United States: experience to date and future directions.

Authors:  David A Fiellin
Journal:  J Addict Med       Date:  2007-06       Impact factor: 3.702

3.  Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.

Authors:  Wendy Kissin; Caroline McLeod; Joseph Sonnefeld; Arlene Stanton
Journal:  J Addict Dis       Date:  2006

4.  A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.

Authors:  P G O'Connor; A H Oliveto; J M Shi; E G Triffleman; K M Carroll; T R Kosten; B J Rounsaville; J A Pakes; R S Schottenfeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

5.  Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.

Authors:  Michael Soyka; Christina Zingg; Gabriele Koller; Heinrich Kuefner
Journal:  Int J Neuropsychopharmacol       Date:  2008-01-21       Impact factor: 5.176

6.  Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.

Authors:  Estelle Lavie; Mélina Fatséas; Cécile Denis; Marc Auriacombe
Journal:  Drug Alcohol Depend       Date:  2008-09-27       Impact factor: 4.492

7.  Office-based management of opioid dependence with buprenorphine: clinical practices and barriers.

Authors:  Alexander Y Walley; Julie K Alperen; Debbie M Cheng; Michael Botticelli; Carolyn Castro-Donlan; Jeffrey H Samet; Daniel P Alford
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

Review 8.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

9.  Six deaths linked to concomitant use of buprenorphine and benzodiazepines.

Authors:  M Reynaud; G Petit; D Potard; P Courty
Journal:  Addiction       Date:  1998-09       Impact factor: 6.526

10.  Home- versus office-based buprenorphine inductions for opioid-dependent patients.

Authors:  Nancy L Sohler; Xuan Li; Hillary V Kunins; Galit Sacajiu; Angela Giovanniello; Susan Whitley; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2009-10-03
View more
  26 in total

1.  Comparing buprenorphine induction experience with heroin and prescription opioid users.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Larissa Mooney; Jacqueline Fahey; Walter Ling
Journal:  J Subst Abuse Treat       Date:  2012-02-01

Review 2.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

3.  Factors associated with buprenorphine versus methadone use in pregnancy.

Authors:  Elizabeth E Krans; Debra Bogen; Gale Richardson; Seo Young Park; Shannon L Dunn; Nancy Day
Journal:  Subst Abus       Date:  2016-02-25       Impact factor: 3.716

4.  The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Roger D Weiss; Larissa Mooney; Jennifer Sharpe Potter; Joshua Lee; Marc N Gourevitch; Walter Ling
Journal:  Am J Addict       Date:  2013-09-24

5.  Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Authors:  Petra Jacobs; Alfonso Ang; Maureen P Hillhouse; Andrew J Saxon; Suzanne Nielsen; Paul G Wakim; Barbara E Mai; Larissa J Mooney; Jennifer S Potter; Jack D Blaine
Journal:  Am J Addict       Date:  2015-09-24

6.  Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.

Authors:  Sharon L Walsh; Sandra D Comer; Michelle R Lofwall; Bradley Vince; Naama Levy-Cooperman; Debra Kelsh; Marion A Coe; Jermaine D Jones; Paul A Nuzzo; Fredrik Tiberg; Behshad Sheldon; Sonnie Kim
Journal:  JAMA Psychiatry       Date:  2017-09-01       Impact factor: 21.596

7.  Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.

Authors:  Daniel Saal; Frank Lee
Journal:  Perm J       Date:  2020-03-13

8.  Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Authors:  Amber M Holbrook; Hendree E Jones; Sarah H Heil; Peter R Martin; Susan M Stine; Gabriele Fischer; Mara G Coyle; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

Review 9.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

10.  Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Authors:  Thomas F Northrup; Angela L Stotts; Charles Green; Jennifer S Potter; Elise N Marino; Robrina Walker; Roger D Weiss; Madhukar Trivedi
Journal:  Addict Behav       Date:  2014-09-28       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.